CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.
Being the founder and CEO of SQZ Biotech is actually Armon Sharei’s first full-time job. He warns that although people often applaud entrepreneurship, lionize its leaders, and paint it as a glamorous adventure, that isn’t really what it’s like.
Can German, American, Chinese, and other companies worldwide work together to advance the mRNA revolution and possibly launch the new “pharmacy of the world?”
While there are many key aspects of a successful international collaboration across many time zones and great distance, in our experience — a collaboration between organizations based in the U.S. and Japan — there are a few essential elements.
Like an ocean liner changing course, the national discussion around “modern” healthcare has moved slowly away from volume toward health outcomes. As such, we in the industry need to be both innovators and advocates for change.
“I’m often asked what it takes to be a successful biotech CEO, and as one of the relatively few female CEOs in our industry, what it takes to break the proverbial glass ceiling.”
Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.
There are some key points for biotech companies to consider as they begin to transform their business model to one that captures the business continuum more fully.
Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.
A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.
The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.
Deborah Waterhouse, CEO of GSK’s joint venture ViiV Healthcare, discusses her three keys to business success.
Intellia Therapeutics CEO, John Leonard, M.D., shares a formative leadership experience from his days at Abbott Laboratories.
Intellia Therapeutics CEO, John Leonard, M.D., provides insight into why he entered industry, and his drive to be an entrepreneur.
The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.
Day 3 of the Netherlands’ biopharma press tour begins with presentations at the Utrecht Science Park (USP).